The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.
Open accessAbstract
Overexpression of the p53 protein, resulting from gene mutations that increase protein stability, has been detected in greater than 25% of primary human breast cancers. In addition, approximately 10% of breast cancer patients have circulating antibodies to the p53 protein. In this study, the anti-p53 humoral response is correlated with the presence and type of mutant p53 protein expressed in the tumor. In a series of 60 breast cancer patients, 0 of 30 tumors with normal, low-level p53 expression induced anti-p53 antibodies, whereas 7 (23%) of 30 tumors with p53 overexpression elicited a specific anti-p53 antibody response. These 7 patients had anti-p53 antibodies that recognized wild-type p53 and a variety of mutant p53 proteins. A comparison of p53 mutations revealed that antibody-negative tumors had mutations exclusively in exons 7 and 8, whereas antibody-positive tumors had mutations primarily in exons 5 and 6. Moreover, all antibody-eliciting tumors contained complexes between p53 and a 70-kDa heat shock protein, whereas none of the antibody-negative tumors contained this complex. This study implicates a 70-kDa heat shock protein in the antigenic presentation of p53.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Deshaies, R. J., Koch, B. D., Werner-Washburne, M., Craig, E. A., & Schekman, R. (1988) · Nature · doi:10.1038/332800a0 · Cited by 1,472
70K heat shock related proteins stimulate protein translocation into microsomes
Chirico, W. J., Waters, M. G., & Blobel, G. (1988) · Nature · doi:10.1038/332805a0 · Cited by 1,232
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211
Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144
Increased expression of mutant forms of p53 oncogene in primary lung cancer
Iggo, R., Bartek, J., Lane, D., Gatter, K., Harris, A. L., & Bartek, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90801-b · Cited by 1,031
p53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,003
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603
Hinds, P., Finlay, C., & Levine, A. J. (1989) · Journal of Virology · doi:10.1128/jvi.63.2.739-746.1989 · Cited by 577
BANKS, L., MATLASHEWSKI, G., & CRAWFORD, L. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09919.x · Cited by 495
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 476
Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke‐Pearson, D. L., Iglehart, J. D., Bast, R. C., & Berchuck, A. (1991) · PubMed · Cited by 464
Self-citationDetection of antibodies against the cellular protein p53 in sera from patients with breast cancer
Crawford, L. V., Pim, D. C., & Bulbrook, R. D. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910300404 · Cited by 450
Specific interaction between the p53 cellular tumour antigen and major heat shock proteins
Pinhasi-Kimhi, O., Michalovitz, D., Ben-Zeev, A., & Oren, M. (1986) · Nature · doi:10.1038/320182a0 · Cited by 329
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53.
Reich, N. C., Oren, M., & Levine, A. J. (1983) · Molecular and Cellular Biology · doi:10.1128/mcb.3.12.2143 · Cited by 312
Genetic basis for p53 overexpression in human breast cancer.
Davidoff, A. M., Humphrey, P. A., Iglehart, J. D., & Marks, J. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.5006 · Cited by 285
Self-citationDifferent Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities
Halevy, O., Michalovitz, D., & Oren, M. (1990) · Science · doi:10.1126/science.2218501 · Cited by 234
Hinds, P. W., Finlay, C. A., Frey, A. B., & Levine, A. J. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2863 · Cited by 232
Mouse p53 inhibits SV40 origin-dependent DNA replication
Braithwaite, A. W., Sturzbecher, H.-W., Addison, C., Palmer, C., Rudge, K., & Jenkins, J. R. (1987) · Nature · doi:10.1038/329458a0 · Cited by 205
Band, V, & Sager, R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.4.1249 · Cited by 194
Hw, S., Chumakov, P. M., Wj, W., & Jenkins, J. R. (1987) · PubMed · Cited by 163
Oligomerization of oncoprotein p53
Kraiss, S., Quaiser, A., Oren, M., & Montenarh, M. (1988) · Journal of Virology · doi:10.1128/jvi.62.12.4737-4744.1988 · Cited by 147
Precise epitope mapping of the murine transformation‐associated protein, p53.
Wade-Evans, A. M., & Jenkins, J. R. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03686.x · Cited by 128
Mutant p53—the commonest genetic abnormality in human cancer?
Harris, A. L. (1990) · The Journal of Pathology · doi:10.1002/path.1711620103 · Cited by 126
VanBuskirk, A. M., DeNagel, D. C., Guagliardi, L. E., Brodsky, F. M., & Pierce, S. K. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.2.500 · Cited by 112
Cited by
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048
Multifactorial analysis of p53 alteration in human cancer: A review
Soussi, T., Legros, Y., Lubin, R., Ory, K., & Schlichtholz, B. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570102 · Cited by 353
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Serum p53 antibodies as early markers of lung cancer
Lubin, R., Zalcman, G., Bouchet, L., Trédaniel, J., Legros, Y., Cazals, D., Hirsch, A., & Soussi, T. (1995) · Nature Medicine · doi:10.1038/nm0795-701 · Cited by 318
Metadata
- Authors
- Davidoff, A. M., Iglehart, J. D., & Marks, J. R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-04-15
- Volume
- 89
- Issue
- 8
- Pages
- 3439-3442
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2016759398
- Cited by
- 272
- References
- 31
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.